1 Pharma Receiving Nice News (NVS)
Motley Fool
NICE reverses position on new use for Novartis' Lucentis
Fierce Pharma
FDA Approves Lucentis (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)
Pipeline Review
Vivus, Onyx, Amarin Await Key Dates in July
Minyanville
PDL BioPharma expects 2 percent revenue growth on better sales of Herceptin, Lucentis, Tysabri
Yahoo/AP
Regeneron drops 6% after Ophthotech reports positive data
The Fly on the Wall

